JonesResearch assumed coverage of Evaxion Biotech with a Buy rating and $10 price target. The firm says the company uses its AI-driven platform to design novel oncology and infectious disease vaccines. Evaxion's "promising" melanoma asset is likely to attract strategic interest, the analyst tells investors in a research note.
